(Q34017642)

30 July 2017

1 reference

title

Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference? (English)

1 reference

30 July 2017

1 reference

1 reference

D Ferrigno

1

1 reference

30 July 2017

G Buccheri

series ordinal

2

1 reference

30 July 2017

publication date

1 August 2000

1 reference

30 July 2017

1 reference

30 July 2017

volume

29

1 reference

30 July 2017

issue

2

1 reference

30 July 2017

page(s)

91-104

1 reference

Chemotherapy of lung cancer

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900112-4

7 January 2021

Cancer statistics, 1993

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900112-4

7 January 2021

Revisions in the International System for Staging Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900112-4

7 January 2021

Retrospective and prospective tumor staging evaluating prognostic factors in operated bronchus carcinoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900112-4

7 January 2021

Incidence of local recurrence and second primary tumors in resected stage I lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900112-4

7 January 2021

Should non-small cell carcinoma of the lung be treated with chemotherapy? Pro: chemotherapy is for non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900112-4

7 January 2021

Chemotherapy and survival of patients with non-small cell lung cancer. A contrary view

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900112-4

7 January 2021

Chemotherapy for non-small cell lung cancer. The continuing challenge

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900112-4

7 January 2021

Chemotherapy and survival in non-small cell lung cancer. The old vexata questio

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900112-4

7 January 2021

Should non-small cell carcinoma of the lung be treated with chemotherapy? Con: therapeutic empiricism--the case against chemotherapy in non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900112-4

7 January 2021

Chemotherapy for metastatic non-small-cell lung cancer--can that dog hunt?

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900112-4

7 January 2021

Is chemotherapy for non-small cell lung cancer worthwhile?

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900112-4

7 January 2021

Palliative chemotherapy for advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900112-4

7 January 2021

Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900112-4

7 January 2021

Polychemotherapy in advanced non small cell lung cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900112-4

7 January 2021

Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900112-4

7 January 2021

Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900112-4

7 January 2021

Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900112-4

7 January 2021

Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900112-4

7 January 2021

Where to go with new expensive treatments in NSCLC.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900112-4

7 January 2021

Chemotherapy in advanced non-small-cell lung cancer. The experience of Italian Cooperative Groups

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900112-4

7 January 2021

Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900112-4

7 January 2021

Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900112-4

7 January 2021

Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900112-4

7 January 2021

Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900112-4

7 January 2021

Paclitaxel/cisplatin in advanced non-small-cell lung cancer (NSCLC)

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900112-4

7 January 2021

Second-line chemotherapy with 96-hour infusional paclitaxel in refractory non-small cell lung cancer: report of a phase II trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900112-4

7 January 2021

Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900112-4

7 January 2021

Carboplatin and paclitaxel for previously treated patients with non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900112-4

7 January 2021

Paclitaxel plus hydroxyurea as second line therapy for non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900112-4

7 January 2021

Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900112-4

7 January 2021

Docetaxel and granulocyte colony-stimulating factor in patients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapy: a multicenter phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900112-4

7 January 2021

Salvage treatment with paclitaxel and gemcitabine for patients with non-small-cell lung cancer after cisplatin- or docetaxel-based chemotherapy: a multicenter phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900112-4

7 January 2021

Second-line chemotherapy with weekly cisplatin and irinotecan in patients with refractory lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900112-4

7 January 2021

Cancer statistics, 1996.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900112-4

7 January 2021

Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900112-4

7 January 2021

Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900112-4

7 January 2021

Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900112-4

7 January 2021

Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900112-4

7 January 2021

10.1016/S0169-5002(00)00112-4

Identifiers

DOI

1 reference

30 July 2017

1 reference